OBJECTIVE: The intestinal flora is thought to play an important role in regulation of immune responses. We investigated the effects of changing the intestinal flora on the course of adjuvant-induced arthritis (AIA) and on experimental autoimmune encephalomyelitis (EAE) by the use of oral antibiotics. METHODS: Oral treatment with either vancomycin or vancomycin, tobramycin, and colistin was started after AIA and EAE induction. Clinical symptoms of AIA and EAE were monitored, and microbial analysis of ileal samples was performed. RESULTS: Oral vancomycin treatment after disease induction significantly decreased clinical symptoms of AIA. Simultaneously, increased concentrations of Escherichia coli were detected in the distal ileum of vancomycin-treated rats. Ileal concentrations of E coli were inversely related to disease scores in rats with AIA. Coadministration of colistin/tobramycin to prevent the increase in E coli abrogated the beneficial effect of vancomycin on AIA. Vancomycin treatment also reduced the clinical symptoms of EAE. CONCLUSION: We propose oral vancomycin as a novel therapeutic strategy in autoimmune diseases.
OBJECTIVE: The intestinal flora is thought to play an important role in regulation of immune responses. We investigated the effects of changing the intestinal flora on the course of adjuvant-induced arthritis (AIA) and on experimental autoimmune encephalomyelitis (EAE) by the use of oral antibiotics. METHODS: Oral treatment with either vancomycin or vancomycin, tobramycin, and colistin was started after AIA and EAE induction. Clinical symptoms of AIA and EAE were monitored, and microbial analysis of ileal samples was performed. RESULTS: Oral vancomycin treatment after disease induction significantly decreased clinical symptoms of AIA. Simultaneously, increased concentrations of Escherichia coli were detected in the distal ileum of vancomycin-treated rats. Ileal concentrations of E coli were inversely related to disease scores in rats with AIA. Coadministration of colistin/tobramycin to prevent the increase in E coli abrogated the beneficial effect of vancomycin on AIA. Vancomycin treatment also reduced the clinical symptoms of EAE. CONCLUSION: We propose oral vancomycin as a novel therapeutic strategy in autoimmune diseases.
Authors: W Van Eden; R Van Der Zee; P Van Kooten; S E Berlo; P M Cobelens; A Kavelaars; C J Heijnen; B Prakken; S Roord; S Albani Journal: Ann Rheum Dis Date: 2002-11 Impact factor: 19.103
Authors: Edward E S Nieuwenhuis; Tetsuya Matsumoto; Dicky Lindenbergh; Rob Willemsen; Arthur Kaser; Ytje Simons-Oosterhuis; Sylvia Brugman; Keizo Yamaguchi; Hiroki Ishikawa; Yuji Aiba; Yasuhiro Koga; Janneke N Samsom; Kenshiro Oshima; Mami Kikuchi; Johanna C Escher; Masahira Hattori; Andrew B Onderdonk; Richard S Blumberg Journal: J Clin Invest Date: 2009-04-06 Impact factor: 14.808
Authors: Mourad Matmati; Peggy Jacques; Jonathan Maelfait; Eveline Verheugen; Mirjam Kool; Mozes Sze; Lies Geboes; Els Louagie; Conor Mc Guire; Lars Vereecke; Yuanyuan Chu; Louis Boon; Steven Staelens; Patrick Matthys; Bart N Lambrecht; Marc Schmidt-Supprian; Manolis Pasparakis; Dirk Elewaut; Rudi Beyaert; Geert van Loo Journal: Nat Genet Date: 2011-08-14 Impact factor: 38.330